Orexo U.S. launches Zubsolv for opioid dependence

Drug designed for use as part of combination drug, counseling therapy

NEW YORK — A drug for treating opioid dependence has been launched, the manufacturer said Monday.

Orexo announced the introduction of Zubsolv (buprenorphine; naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is designed for use as part of a broader treatment regimen that combines drug therapy and counseling.

The Food and Drug Administration approved Zubsolv in July of this year. Opioid dependence affects nearly 5 million people in the United States, according to a July 2002 study, and while treatable, 60% of those who have it don't receive treatment.

Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

Login or Register to post a comment.